Berndt A. E. Modig
Founder bij PHARVARIS N.V.
Vermogen: 35 M $ op 31-03-2024
Oorsprong van het eerstegraads netwerk van Berndt A. E. Modig
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Pricewaterhouse LLP
82
| Extinct | Miscellaneous Commercial Services | 82 |
| Private Company | Pharmaceuticals: Major | 39 | |
| Public Company | Miscellaneous Commercial Services | 31 | |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY.
23
| Subsidiary | Pharmaceuticals: Major | 23 |
22
| Public Company | Biotechnology | 22 |
| Public Company | Pharmaceuticals: Major | 22 | |
| Extinct | Pharmaceuticals: Major | 21 | |
| Extinct | Biotechnology | 10 | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland.
10
| Subsidiary | Pharmaceuticals: Major | 10 |
Centogene AG
 Centogene AG Medical/Nursing ServicesHealth Services Centogene AG focuses on genetic and biochemical diagnostic testing services for rare hereditary disorders. The firm operates through the offices located in Freiburg, Dubai and Noida. The company was founded by Arndt Rolfs in 2006 and is headquartered in Rostock, Germany.
10
| Holding Company | Medical/Nursing Services | 10 |
Auris Medical Holding AG /Old/
 Auris Medical Holding AG /Old/ Medical SpecialtiesHealth Technology Auris Medical Holding AG engages in the research, development, and commercialization of pharmaceutical products for inner ear disorders. Its products portfolio targets to treat tinnitus, Menière's disease, and hearing loss. The company was founded by Thomas Meyer on April 1, 1998 and is headquartered in Zug, Switzerland.
7
| Extinct | Medical Specialties | 7 |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
| Public Company | Biotechnology | 5 | |
Surplex AG
 Surplex AG Internet Software/ServicesTechnology Services Surplex AG operates an online business-to-business exchange for surplus assets and excess inventory. The private company is based in Dusseldorf, Germany.
1
| Private Company | Internet Software/Services | 1 |
OncoBiotek SA
 OncoBiotek SA BiotechnologyHealth Technology OncoBiotek SA engages in the provision of biotechnology research and development. The company was founded on January 1, 2009 and is headquartered in Châteauneuf-Villevieille, France.
1
| Private Company | Biotechnology | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Berndt A. E. Modig via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| HILL-ROM HOLDINGS, INC. | Hospital/Nursing Management | Director of Finance/CFO Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| QIAGEN N.V. | Medical Specialties | Chief Executive Officer Director/Board Member Corporate Officer/Principal | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
| ARBUTUS BIOPHARMA CORPORATION | Pharmaceuticals: Major | Director/Board Member Chairman Chairman Director/Board Member | |
| ROIVANT SCIENCES LTD. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer Chairman Corporate Officer/Principal Comptroller/Controller/Auditor Chief Executive Officer President Director of Finance/CFO | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Public Communications Contact Director of Finance/CFO | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| EVOTEC SE | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member Director/Board Member Chairman | |
| SCYNEXIS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| Brandeis University | College/University | Undergraduate Degree Doctorate Degree | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director of Finance/CFO | |
| MEDIVATION INC | Pharmaceuticals: Major | Founder Founder Corporate Officer/Principal Chief Operating Officer | |
| Erasmus University Rotterdam | College/University | Graduate Degree Graduate Degree | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Doctorate Degree | |
| Katholieke Universiteit Leuven | College/University | Doctorate Degree Doctorate Degree Undergraduate Degree | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Undergraduate Degree | |
Medivation Neurology LLC
 Medivation Neurology LLC BiotechnologyHealth Technology Part of Pfizer Inc., Medivation Neurology LLC develops and produces biopharmaceutical products. The private company is based in San Francisco, CA. | Biotechnology | Chief Executive Officer Director of Finance/CFO | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member Director/Board Member | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| Harvard Medical School | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer Corporate Officer/Principal | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| Harvard College | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Chief Executive Officer Chief Operating Officer | |
Axovant Sciences, Inc.
 Axovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sio Gene Therapies, Inc., Axovant Sciences, Inc. is a private company that manufactures and distributes pharmaceutical products. The company is based in New York, NY. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director of Finance/CFO Director of Finance/CFO Director of Finance/CFO Chairman Chief Executive Officer Chief Executive Officer | |
| MYOVANT SCIENCES LTD. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Chairman Director/Board Member Director/Board Member Corporate Officer/Principal | |
Dermavant Sciences, Inc.
 Dermavant Sciences, Inc. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Dermavant Sciences, Inc. develops biological products. The private company is based in Raleigh, NC. Todd Zavodnick has been the CEO of the company since 2018. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The private company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Tech/Sci/R&D Officer | |
| UROVANT SCIENCES LTD. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Arvelle Therapeutics International GmbH
 Arvelle Therapeutics International GmbH BiotechnologyHealth Technology Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member Founder Chairman Founder | |
Dermavant Sciences Ltd.
 Dermavant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company which focuses on developing and commercializing therapeutics in medical dermatology. The company is developing a pipeline of therapies in medical dermatology and is currently advancing development programs for five product candidates which targets specific unmet needs in two of the immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis and acne. The company was founded on September 28, 2015 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman | |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member Chief Operating Officer | |
Immunovant Sciences Ltd.
 Immunovant Sciences Ltd. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Immunovant Sciences Ltd. develops restorative therapies for autoimmune diseases. The private company is based in Hamilton, Bermuda. Immunovant Sciences was acquired by Health Sciences Acquisitions Corp. from Roivant Sciences Ltd. on December 19, 2019 for $863.06 million. | Biotechnology | Director/Board Member Director/Board Member Chairman | |
Auris Medical AG
 Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| IMMUNOVANT, INC. | Biotechnology | Director/Board Member Director/Board Member Chairman Director/Board Member | |
Kriya Therapeutics, Inc.
 Kriya Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kriya Therapeutics, Inc. designs and develops transformative new treatments for prevalent and severe chronic diseases. The company was founded by Shankar Ramaswamy and Roger Jeffs and is headquartered in Redwood City, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chief Executive Officer Corporate Officer/Principal | |
| Roivant Social Ventures, Inc. | Director/Board Member Director/Board Member Director/Board Member | ||
Vico Therapeutics BV
 Vico Therapeutics BV BiotechnologyHealth Technology Vico Therapeutics BV is a private biotech company based in Leiden, Netherlands that focuses on developing RNA modulating therapies for rare severe neurological disorders. The Dutch company's antisense oligonucleotide platform (AON) is directed towards different forms of spinocerebellar ataxia (SCA) and Huntington disease (HD), while its early discovery RNA editing platform is directed towards Rett syndrome. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Gail Mandel, and Dr. Judith van Deutekom, who have strong academic reputations and vast industry experience. Micah Mackison has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Director/Board Member Founder |
Statistieken
Internationaal
| Verenigde Staten | 25 |
| Verenigd Koninkrijk | 6 |
| Nederland | 6 |
| Zwitserland | 6 |
| Duitsland | 4 |
Sectoraal
| Health Technology | 33 |
| Consumer Services | 11 |
| Commercial Services | 5 |
| Finance | 3 |
| Health Services | 2 |
Operationeel
| Director/Board Member | 619 |
| Corporate Officer/Principal | 207 |
| Independent Dir/Board Member | 154 |
| Chairman | 152 |
| Chief Executive Officer | 107 |
Sterkste connecties
| Insiders | |
|---|---|
| Peer Schatz | 83 |
| Pierre Legault | 45 |
| Alain Munoz | 38 |
| George Bickerstaff | 37 |
| Frank Torti | 35 |
| Flemming Ørnskov | 34 |
| Martijn Kleijwegt | 33 |
| Rémi Droller | 29 |
| Clarence Machado | 29 |
| Hubert Birner | 27 |
| Luc Dochez | 26 |
| David Hung | 24 |
| Lawrence Olanoff | 22 |
| Mathieu Simon | 22 |
| Kenneth Ludlum | 22 |
- Beurs
- Insiders
- Berndt A. E. Modig
- Bedrijfsconnecties
